Abstract
The present investigation was designed to examine the effect of four atrial peptide hormones with vasodilatory properties on the circulating immunoreactive (ir) levels of the vasoconstrictive peptide endothelin (ET) in 36 healthy human subjects. Circulating levels of human ET and cyclic guanosine monophosphate ([cGMP], a potential mediator of the effects of atrial peptides), were measured every 30 minutes during 1-hour preinfusion, 1-hour infusion, and 3-hour postinfusion periods. Atrial natriuretic factor ([ANF] amino acid (aa) 99 to 126 of the 126-aa ANF prohormone) and kaliuretic peptide (aa 79 to 98 of this same prohormone) significantly (P<.05) decreased circulating ET concentrations. Kaliuretic peptide effects were early and ANF effects were delayed until kaliuretic peptide effects began to wane. Long-acting natriuretic peptide (LANP), consisting of aa 1 to 30 of the ANF prohormone, on the other hand, significantly (P<.05) increased ET circulating concentrations during a 1-hour infusion period. The increase in ET in the circulation secondary to LANP became nonsignificant, although it was still elevated, within 30 minutes of ceasing LANP infusion. Vessel dilator, consisting of aa 31 to 67 of the ANF prohormone, and infusio...Continue Reading
References
Apr 1, 1992·Hypertension·M KohnoT Takeda
Oct 1, 1992·Kidney International·M KohnoT Takeda
Aug 11, 1992·Mayo Clinic Proceedings·R J RodehefferJ C Burnett
May 1, 1992·Journal of Clinical Pharmacology·B H AckermanA L Sallman
Mar 1, 1992·Journal of Vascular Research·M KohnoT Takeda
Jun 1, 1991·The Journal of Clinical Investigation·M KohnoT Takeda
Aug 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·M L De FeoG D Aurbach
Oct 1, 1991·Journal of Hypertension·E SuzukiT Sugimoto
Sep 1, 1991·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·G M Rubanyi, L H Botelho
Jun 1, 1990·Metabolism: Clinical and Experimental·M KohnoT Takeda
Apr 1, 1990·Acta Physiologica Scandinavica·K P OhmanH R Keiser
Dec 14, 1990·Biochemical and Biophysical Research Communications·O SaijonmaaF Fyhrquist
Mar 31, 1988·Nature·M YanagisawaT Masaki
Sep 1, 1989·Circulation·C J WintersD L Vesely
Dec 1, 1989·Proceedings of the Society for Experimental Biology and Medicine·D L VeselyM Epstein
Jan 1, 1989·Life Sciences·J P StaschD Neuser
Jan 1, 1989·The Journal of Clinical Investigation·W L MillerJ C Burnett
Mar 13, 1989·FEBS Letters·K AndoF Marumo
Jun 15, 1989·Biochemical and Biophysical Research Communications·P Cernacek, D J Stewart
Sep 1, 1989·American Journal of Hypertension·K YokokawaT Takeda
Nov 13, 1987·Biochemical and Biophysical Research Communications·D L VeselyD A Baeyens
May 1, 1985·The American Journal of Physiology·K A HickeyR F Highsmith
Jul 1, 1981·Infection and Immunity·D L VeselyT P Monson
Jan 1, 1994·Peptides·W R GowerD L Vesely
Sep 1, 1994·Circulation·D L VeselyD D Schocken
Jan 1, 1993·Life Sciences·J UemasuH Kawasaki
Citations
May 20, 1998·Metabolism: Clinical and Experimental·L MessaoudiJ Kolanowski
Feb 15, 2001·Critical Care Medicine·K J HarteminkL G Thijs
Apr 16, 2004·Journal of Cardiovascular Pharmacology·Paul MulderChristian Thuillez
Sep 8, 2007·Canadian Journal of Physiology and Pharmacology·Shyam S Mohapatra
Sep 10, 2004·The Journal of Allergy and Clinical Immunology·Shyam S MohapatraWilliam R Gower
Feb 17, 1998·Cardiovascular Research·S DaggubatiD L Vesely
Jan 4, 2008·Cancer Research·Xiaoyuan KongShyam S Mohapatra